Annette Insurance (AWH, Financial) experienced a significant stock drop, falling 6.19%. The stock is currently priced at $0.910 per share with a trading volume of 82,577 shares, a turnover rate of 0.51%, and a price swing of 9.28%.
Recent financial reports reveal AWH had a revenue of $2.42 million but reported a net loss of $3.53 million, translating to an earnings per share (EPS) of -$0.28. The gross profit stood at $1.42 million, and the price-to-earnings (P/E) ratio was -0.66. Currently, there are no institutional ratings available in terms of buy, hold, or sell recommendations for the stock.
Within the life sciences industry, where AWH operates, the overall decline was 0.02%. Other notable stocks in this sector showed substantial movements, including significant gains from Aclaris Therapeutics, Inc., Personalis, Inc., and Bioaffinity Technologies, Inc. Active trading was observed in Endra Life Sciences Inc., Applied Dna Sciences, Inc., and Aclaris Therapeutics, Inc., with turnover rates of 15.89%, 7.73%, and 5.96%, respectively. Endra Life Sciences Inc., Aclaris Therapeutics, Inc., and T2 Biosystems, Inc. reported considerable price swings with amplitudes of 19.15%, 15.50%, and 12.71%, respectively.
Aspira Women's Health Inc, the company behind Annette Insurance, focuses on the development and commercialization of diagnostic tests for gynecological diseases. Their product line includes OvaSuite, a set of blood tests using proprietary algorithms and patient characteristics, OvaWatch for assessing ovarian cancer risk in women with adnexal masses, and Ova1Plus, two FDA-approved tests combined for evaluating pelvic masses ahead of planned surgeries.
